Chronic Lymphocytic Leukemia (CLL) – Epidemiology, Pathogenesis, Morphology, Clinical Features

What is Chronic Lymphocytic Leukemia (CLL)?

  • CLL is a peripheral B-cell neoplasm and the most common leukemia in adults in the Western world.

  • It has a closely related counterpart called Small Lymphocytic Lymphoma (SLL).

  • The difference lies mainly in the blood counts:

    • CLL shows absolute lymphocytosis (>5000/mm³) in peripheral blood.

    • SLL is primarily a lymph node–based neoplasm (a type of Non-Hodgkin lymphoma) without significant blood lymphocytosis.

Epidemiology

  • Age: Common around 60 years.

  • Gender: More common in males than females.

  • SLL accounts for only ~4% of all non-Hodgkin lymphomas.

Pathogenesis – How Does Chronic Lymphocytic Leukemia (CLL) Develop?

Unlike many other lymphoid malignancies, chromosomal translocations are rare in CLL. Instead, certain chromosomal deletions and mutations play key roles.

1. Chromosomal Abnormalities

  • Most common: Deletion of long arm of chromosome 13 (del13q)

  • Others: del11q, del17p, and trisomy 12

2. Role of microRNAs

  • The deleted 13q region encodes microRNA-15A and microRNA-16-1, which act as tumor suppressors.

  • Their loss leads to overexpression of BCL2 (an anti-apoptotic protein) → reduced apoptosis → accumulation of long-lived lymphocytes.

3. Somatic Hypermutation Status

  • Normally occurs in germinal center B cells to improve antibody affinity.

  • Mutated immunoglobulin genes (with somatic hypermutation): indicate origin from post–germinal center memory B cells → better prognosis

  • Unmutated genes (no somatic hypermutation): indicate naive B-cell origin → more aggressive disease

4. NOTCH1 and RNA Splicing Mutations

  • NOTCH1 gain-of-function mutations seen in 10–18% cases → associated with poor prognosis

  • RNA splicing gene mutations also occur.

Summary of genetic changes:

  • del13q → ↓miR15/16 → ↑BCL2 → ↓apoptosis → lymphocyte accumulation

  • Unmutated Ig genes → aggressive; Mutated Ig genes → better outcome

  • NOTCH1 and RNA splicing mutations → poor prognosis

Tumor Microenvironment and Growth

  • Proliferation centers in lymph nodes are key growth zones.

  • Stromal cells in these centers release:

    • NF-κB → promotes cell survival

    • MYC → promotes proliferation

  • B-cell receptor (BCR) signaling pathway via BTK (Bruton Tyrosine Kinase) is crucial.

    • BTK inhibitors like Ibrutinib block this pathway and show good therapeutic response.

Morphology  of Chronic Lymphocytic Leukemia (CLL)

Peripheral Blood

  • Numerous small lymphocytes with:

    • Dense chromatin

    • Very scant cytoplasm

  • Smudge cells (basket cells) — fragile nuclei crushed during smear preparation.

    • Highly characteristic, but not specific (can appear in other conditions too).

Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia (CLL)

Lymph Node (SLL)

  • Diffuse effacement of nodal architecture (no cortex/medulla)

  • Sheets of small lymphocytes

  • Proliferation centers — loose aggregates of larger activated lymphocytes

Immunophenotype

CLL/SLL cells express:

  • Pan B-cell markers: CD19, CD20

  • CD23 and CD5 co-expression

  • Low-level surface immunoglobulin (usually IgM, sometimes IgD/IgG/IgT)

  • High BCL2 expression

Clinical Features of Chronic Lymphocytic Leukemia (CLL)

  • Often asymptomatic at diagnosis

  • Symptoms, if present:

    • Fatigue, weight loss, anorexia

    • Generalized lymphadenopathy

    • Hepatosplenomegaly (in 50–60% cases)

Immune Dysfunction

  • Despite high lymphocyte counts, normal immune function is disrupted

  • Hypogammaglobulinemia → increased bacterial infections

  • Autoantibodies → autoimmune hemolytic anemia or thrombocytopenia (10–15% cases)

Staging of Chronic Lymphocytic Leukemia (CLL)

There are two staging systems:

Rai Classification (Used in USA)

  • Stage 0: Lymphocytosis (>10,000/mm³ or >30% marrow lymphocytes)

  • Stage I: Stage 0 + lymphadenopathy

  • Stage II: Stage 0 + hepatomegaly or splenomegaly

  • Stage III: Stage 0 + anemia (Hb <11 g/dL)

  • Stage IV: Stage 0 + thrombocytopenia (platelets <1 lakh/mm³)

  • Stages III and IV represent advanced disease (marrow infiltration suppressing hematopoiesis).

Binet Classification (Used in Europe)

  • Stage A: Lymphocytosis; Hb >10 g/dL; Platelets >1 lakh/mm³; <2 involved sites

  • Stage B: Same as A, but 3–5 involved sites

  • Stage C: A/B + Hb <10 g/dL or platelets <1 lakh/mm³

Involved sites include cervical, axillary, inguinal nodes, liver, and spleen.

Treatment of Chronic Lymphocytic Leukemia (CLL)

  • Evolving; multiple modalities:

    • BCL2 inhibitors

    • Anti-CD20 antibodies

    • BTK inhibitors (e.g. Ibrutinib)

  • These are chosen based on stage, age, and genetic profile.

Prognosis of Chronic Lymphocytic Leukemia (CLL)

  • Median survival ~10 years

  • Worse prognosis with:

    • Advanced stage (Rai III/IV or Binet C)

    • del11q, del17p (TP53)

    • Unmutated Ig genes

    • NOTCH1 mutation

    • ZAP70 expression (enhances Ig receptor signaling)

Richter Transformation in Chronic Lymphocytic Leukemia (CLL)

  • In 5–10% cases, CLL/SLL can transform to Diffuse Large B-Cell Lymphoma (DLBCL)

  • Known as Richter Syndrome

  • Presents as rapidly enlarging lymph node or splenic mass

  • Involves additional TP53 and MYC mutations

  • Has a very poor prognosis

Key Takeaways

  • CLL is the most common adult leukemia

  • Originates from B-cells with various genetic alterations and microenvironmental support

  • Shows smudge cells in blood and proliferation centers in lymph nodes

  • Immune dysfunction is common despite high lymphocyte counts

  • Stage and genetic profile determine prognosis

  • Richter transformation is a dangerous complication

CLICK HERE to view the video tutorial on chronic lymphocytic leukemia